<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34635126</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Molecular brain</Title><ISOAbbreviation>Mol Brain</ISOAbbreviation></Journal><ArticleTitle>Bisperoxovanadium promotes motor neuron survival and neuromuscular innervation in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>155</StartPage><MedlinePgn>155</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">155</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13041-021-00867-7</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common motor neuron (MN) disease, with no present cure. The progressive loss of MNs is the hallmark of ALS. We have previously shown the therapeutic effects of the phosphatase and tensin homolog (PTEN) inhibitor, potassium bisperoxo (picolinato) vanadium (bpV[pic]), in models of neurological injury and demonstrated significant neuroprotective effects on MN survival. However, accumulating evidence suggests PTEN is detrimental for MN survival in ALS. Therefore, we hypothesized that treating the mutant superoxide dismutase 1 G93A (mSOD1<sup>G93A</sup>) mouse model of ALS during motor neuron degeneration and an in vitro model of mSOD1<sup>G93A</sup> motor neuron injury with bpV(pic) would prevent motor neuron loss. To test our hypothesis, we treated mSOD1<sup>G93A</sup> mice intraperitoneally daily with 400&#xa0;&#x3bc;g/kg bpV(pic) from 70 to 90&#xa0;days of age. Immunolabeled MNs and microglial reactivity were analyzed in lumbar spinal cord tissue, and bpV(pic) treatment significantly ameliorated ventral horn motor neuron loss in mSOD1<sup>G93A</sup> mice (p&#x2009;=&#x2009;0.003) while not significantly altering microglial reactivity (p&#x2009;=&#x2009;0.701). Treatment with bpV(pic) also significantly increased neuromuscular innervation (p&#x2009;=&#x2009;0.018) but did not affect muscle atrophy. We also cultured motor neuron-like NSC-34 cells transfected with a plasmid to overexpress mutant SOD1<sup>G93A</sup> and starved them in serum-free medium for 24&#xa0;h with and without bpV(pic) and downstream inhibitor of Akt signaling, LY294002. In vitro, bpV(pic) improved neuronal viability, and Akt inhibition reversed this protective effect (p&#x2009;&lt;&#x2009;0.05). In conclusion, our study indicates systemic bpV(pic) treatment could be a valuable neuroprotective therapy for ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junmei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tierney</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Ranjeet</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonsway</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Chandler L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-8616-8263</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN, 46202, USA. chalwalk@iu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Research Group, Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, IN, 46202, USA. chalwalk@iu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IK2 RX002688</GrantID><Acronym>RX</Acronym><Agency>RRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Brain</MedlineTA><NlmUniqueID>101468876</NlmUniqueID><ISSNLinking>1756-6606</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002867">Chromones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016895">Culture Media, Serum-Free</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009025">Morpholines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017968">Vanadium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C472777">bisperoxovanadium</NameOfSubstance></Chemical><Chemical><RegistryNumber>31M2U1DVID</RegistryNumber><NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C514862">Akt1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.67</RegistryNumber><NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.67</RegistryNumber><NameOfSubstance UI="C494929">PTEN protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000870" MajorTopicYN="N">Anterior Horn Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016895" MajorTopicYN="N">Culture Media, Serum-Free</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051059" MajorTopicYN="N">PTEN Phosphohydrolase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017968" MajorTopicYN="N">Vanadium Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Akt</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Motor neuron</Keyword><Keyword MajorTopicYN="N">PTEN</Keyword><Keyword MajorTopicYN="N">bpV</Keyword></KeywordList><CoiStatement>No authors of the manuscript declare any conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34635126</ArticleId><ArticleId IdType="pmc">PMC8507234</ArticleId><ArticleId IdType="doi">10.1186/s13041-021-00867-7</ArticleId><ArticleId IdType="pii">10.1186/s13041-021-00867-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225&#x2013;238. doi: 10.1016/B978-0-12-802973-2.00013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopford MJ, Higginbottom A, Hautbergue GM, Cooper-Knock J, Mulcahy PJ, De Vos KJ, et al. C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten. Hum Mol Genet. 2017;26(6):1133&#x2013;1145. doi: 10.1093/hmg/ddx022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx022</ArticleId><ArticleId IdType="pmc">PMC5409131</ArticleId><ArticleId IdType="pubmed">28158451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J, Ning K, Ferraiuolo L, Heath PR, Ismail A, Kuo SW, et al. Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain. 2011;134(Pt 2):506&#x2013;517. doi: 10.1093/brain/awq345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq345</ArticleId><ArticleId IdType="pmc">PMC3030763</ArticleId><ArticleId IdType="pubmed">21228060</ArticleId></ArticleIdList></Reference><Reference><Citation>Little D, Valori CF, Mutsaers CA, Bennett EJ, Wyles M, Sharrack B, et al. PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy. Mol Ther. 2015;23(2):270&#x2013;277. doi: 10.1038/mt.2014.209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.209</ArticleId><ArticleId IdType="pmc">PMC4445616</ArticleId><ArticleId IdType="pubmed">25369768</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker CL, Walker MJ, Liu NK, Risberg EC, Gao X, Chen J, et al. Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PLoS ONE. 2012;7(1):e30012. doi: 10.1371/journal.pone.0030012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030012</ArticleId><ArticleId IdType="pmc">PMC3254642</ArticleId><ArticleId IdType="pubmed">22253859</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker CL, Xu XM. PTEN inhibitor bisperoxovanadium protects oligodendrocytes and myelin and prevents neuronal atrophy in adult rats following cervical hemicontusive spinal cord injury. Neurosci Lett. 2014;573:64&#x2013;68. doi: 10.1016/j.neulet.2014.02.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.02.039</ArticleId><ArticleId IdType="pmc">PMC4055541</ArticleId><ArticleId IdType="pubmed">24582904</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker CL, Wu X, Liu NK, Xu XM. Bisperoxovanadium mediates neuronal protection through inhibition of PTEN and activation of PI3K/AKT-mTOR signaling after traumatic spinal injuries. J Neurotrauma. 2019;36(18):2676&#x2013;2687. doi: 10.1089/neu.2018.6294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2018.6294</ArticleId><ArticleId IdType="pmc">PMC6727469</ArticleId><ArticleId IdType="pubmed">30672370</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Olivan S, Mancera P, Pasten-Zamorano A, Manzano R, Casas C, et al. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13(3):302&#x2013;310. doi: 10.3109/17482968.2012.662688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.662688</ArticleId><ArticleId IdType="pubmed">22424126</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung YT, Peng KC, Chen YC, Yen YP, Chang M, Thams S, et al. Mir-17-92 confers motor neuron subtype differential resistance to ALS-associated degeneration. Cell Stem Cell. 2019;25(2):193&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">31155482</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Qin J, Lan L, Zhang H, Liu F, Wu Z, et al. PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism. Cancer Biol Ther. 2015;16(2):297&#x2013;306. doi: 10.1080/15384047.2014.1002353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384047.2014.1002353</ArticleId><ArticleId IdType="pmc">PMC4622010</ArticleId><ArticleId IdType="pubmed">25756512</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikatza-Menoio O, Elicegui A, Bengoetxea X, Naldaiz-Gastesi N, Lopez de Munain A, Gerenu G, et al. The skeletal muscle emerges as a new disease target in amyotrophic lateral sclerosis. J Pers Med. 2021;11(7):1. doi: 10.3390/jpm11070671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11070671</ArticleId><ArticleId IdType="pmc">PMC8307751</ArticleId><ArticleId IdType="pubmed">34357138</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid AC, Byrne RD, Vilar R, Woscholski R. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004;566(1&#x2013;3):35&#x2013;38. doi: 10.1016/j.febslet.2004.03.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2004.03.102</ArticleId><ArticleId IdType="pubmed">15147864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Shao J, Huang R, Guan Y, Li G, Chen S, et al. Targeting PTEN to regulate autophagy and promote the repair of injured neurons. Brain Res Bull. 2020;165:161&#x2013;168. doi: 10.1016/j.brainresbull.2020.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2020.10.008</ArticleId><ArticleId IdType="pubmed">33049350</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>